☰

Mandana Nikpour, Ph.D. - Publications

Affiliations: 
2011 University of Toronto, Toronto, ON, Canada 
Area:
Medicine and Surgery, Public Health
Tree Info Similar researchers PubMed Report error

144 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Golder V, Kandane-Rathnayake R, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, ... ... Nikpour M, et al. Comparison Of Attainment And Protective Effects Of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established SLE. The Journal of Rheumatology. PMID 38490668 DOI: 10.3899/jrheum.2023-0900  0.323
2024 Katsumata Y, Inoue E, Harigai M, Cho J, Louthrenoo W, Hoi A, Golder V, Lau CS, Lateef A, Chen YH, Luo SF, Wu YJ, Hamijoyo L, Li Z, Sockalingam S, ... ... Nikpour M, et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Annals of the Rheumatic Diseases. PMID 38423757 DOI: 10.1136/ard-2023-225369  0.338
2024 Nielsen W, Strand V, Simon LS, Parodis I, Kim AHJ, Desai M, Enman Y, Wallace D, Chaichian Y, Navarra S, Aranow C, MacKay M, Trotter K, Tayer-Shifman OE, Duarte-Garcia A, ... ... Nikpour M, et al. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set. Seminars in Arthritis and Rheumatism. 65: 152380. PMID 38281467 DOI: 10.1016/j.semarthrit.2024.152380  0.522
2023 Cho J, Shen L, Huq M, Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Hamijoyo L, Luo SF, Wu YJ, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, ... ... Nikpour M, et al. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study. The Lancet. Rheumatology. 5: e584-e593. PMID 38251484 DOI: 10.1016/S2665-9913(23)00209-6  0.332
2022 Connelly K, Kandane-Rathnayake R, Hoi A, Louthrenoo W, Hamijoyo L, Cho J, Lateef A, Fen Luo S, Wu YJ, Li Z, Navarra S, Zamora L, Sockalingam S, Hao Y, Zhang Z, ... ... Nikpour M, et al. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study. The Lancet. Rheumatology. 4: e831-e841. PMID 38261391 DOI: 10.1016/S2665-9913(22)00307-1  0.317
2022 Kandane-Rathnayake R, Golder V, Louthrenoo W, Chen YH, Cho J, Lateef A, Hamijoyo L, Luo SF, Wu YJ, Navarra SV, Zamora L, Li Z, Sockalingam S, Katsumata Y, Harigai M, ... ... Nikpour M, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. The Lancet. Rheumatology. 4: e822-e830. PMID 38261390 DOI: 10.1016/S2665-9913(22)00304-6  0.351
2022 Ross L, Proudman S, Walker J, Stevens W, Ferdowsi N, Quinlivan A, Morrisroe K, Baron M, Nikpour M. Evaluation of patient and physician assessments of gastrointestinal disease activity in systemic sclerosis. The Journal of Rheumatology. PMID 36379565 DOI: 10.3899/jrheum.220832  0.355
2022 Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo SF, Wu YJ, Chen YH, Cho J, Lateef A, Hamijoyo L, Navarra SV, Zamora L, Sockalingam S, An Y, Li Z, Katsumata Y, ... ... Nikpour M, et al. 'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Research & Therapy. 24: 70. PMID 35287720 DOI: 10.1186/s13075-022-02756-3  0.333
2022 Jerjen R, Nikpour M, Krieg T, Denton CP, Saracino AM. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis. Journal of the American Academy of Dermatology. PMID 35131402 DOI: 10.1016/j.jaad.2021.10.065  0.317
2021 Hao Y, Oon S, Ji L, Gao D, Fan Y, Geng Y, Zhang X, Li G, Morand EF, Nikpour M, Zhang Z. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clinical Rheumatology. PMID 34595670 DOI: 10.1007/s10067-021-05940-z  0.302
2021 Kandane-Rathnayake R, Louthrenoo W, Golder V, Luo SF, Wu YJ, Lateef A, Cho J, Li Z, An Y, Hamijoyo L, Navarra S, Zamora L, Katsumata Y, Harigai M, Sockalingam S, ... ... Nikpour M, et al. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study. Rheumatology (Oxford, England). PMID 33693676 DOI: 10.1093/rheumatology/keab217  0.331
2020 Patel S, Morrisroe K, Proudman S, Hansen D, Sahhar J, Sim MR, Ngian GS, Walker J, Strickland G, Wilson M, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M, et al. Occupational silica exposure in an Australian systemic sclerosis cohort. Rheumatology (Oxford, England). PMID 32911541 DOI: 10.1093/Rheumatology/Keaa446  0.361
2020 Ross L, Stevens W, Wilson M, Huq M, Strickland G, Walker J, Sahhar J, Ngian GS, Roddy J, Youssef P, Proudman S, Nikpour M. Performance of the 2017 EUSTAR activity index in an scleroderma cohort. Clinical Rheumatology. PMID 32696281 DOI: 10.1007/S10067-020-05126-Z  0.425
2020 Nikpour M, Teh B, Wicks IP, Pellegrini M. Correspondence regarding research letter to the editor by Mathian , 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'. Annals of the Rheumatic Diseases. PMID 32471898 DOI: 10.1136/Annrheumdis-2020-217827  0.424
2020 Koelmeyer R, Nim HT, Nikpour M, Sun YB, Kao A, Guenther O, Morand E, Hoi A. High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus. Lupus Science & Medicine. 7. PMID 32467293 DOI: 10.1136/Lupus-2019-000372  0.44
2020 Askanase A, Oon S, Huq M, Calderone A, Morand EF, Nikpour M, Aranow C. Response to: 'Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?' by Chessa . Annals of the Rheumatic Diseases. PMID 32461205 DOI: 10.1136/Annrheumdis-2020-217692  0.323
2020 Askanase A, Oon S, Huq M, Calderone A, Morand EF, Nikpour M, Aranow C. Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen . Annals of the Rheumatic Diseases. PMID 32434819 DOI: 10.1136/Annrheumdis-2020-217687  0.39
2020 Aranow C, Askanase A, Oon S, Huq M, Calderone A, Morand EF, Nikpour M. Laboratory investigation results influence Physician's lobal ssessment (PGA) of disease activity in SLE. Annals of the Rheumatic Diseases. PMID 32241797 DOI: 10.1136/Annrheumdis-2019-216753  0.437
2020 Fairley JL, Hansen D, Proudman S, Sahhar J, Ngian GS, Walker J, Strickland G, Wilson M, Morrisroe K, Ferdowsi N, Major G, Roddy J, Stevens W, Nikpour M. Clinical characteristics and survival in systemic sclerosis-mixed connective tissue disease and systemic sclerosis-overlap syndrome. Arthritis Care & Research. PMID 32058672 DOI: 10.1002/Acr.24167  0.418
2020 Hao Y, Ji L, Gao D, Fan Y, Morand EF, Nikpour M, Zhang Z. Ab0376 Determinants And Protective Effects Of A Low Disease Activity State In Systemic Lupus Erythematosus: Results From A Prospective Chinese Cohort Annals of the Rheumatic Diseases. 79: 1488-1489. DOI: 10.1136/Annrheumdis-2020-Eular.807  0.36
2020 Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu YJ, Chen YH, Golder V, Lateef A, Cho J, Navarra S, Zamora L, Hamijoyo L, Sockalingam S, An Y, Li Z, Katsumata Y, ... ... Nikpour M, et al. Ab0384 Medication Use In Systemic Lupus Erythematosus – Data From A Multicentre Cohort Study Annals of the Rheumatic Diseases. 79: 1492-1493. DOI: 10.1136/Annrheumdis-2020-Eular.3007  0.351
2020 Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y, Lateef A, Golder V, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, ... ... Nikpour M, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study The Lancet Rheumatology. 2: e24-e30. DOI: 10.1016/s2665-9913(19)30105-5  0.38
2019 Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, ... ... Nikpour M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. The Lancet. Rheumatology. 1: e95-e102. PMID 38229349 DOI: 10.1016/S2665-9913(19)30037-2  0.321
2019 Golder V, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, ... ... Nikpour M, et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. The Lancet. Rheumatology. 1: e103-e110. PMID 38229337 DOI: 10.1016/S2665-9913(19)30048-7  0.373
2019 Morrisroe K, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hill CL, Roddy J, Walker J, Proudman S, Nikpour M. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Research & Therapy. 21: 299. PMID 31870459 DOI: 10.1186/S13075-019-2080-Y  0.352
2019 Morrisroe K, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hansen D, Patel S, Hill CL, Roddy J, Walker J, Proudman S, Nikpour M. The economic burden of systemic sclerosis related pulmonary arterial hypertension in Australia. Bmc Pulmonary Medicine. 19: 226. PMID 31775705 DOI: 10.1186/S12890-019-0989-1  0.332
2019 Morrisroe K, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hansen D, Patel S, Hill CL, Roddy J, Walker J, Proudman S, Nikpour M. The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology (Oxford, England). PMID 31740961 DOI: 10.1093/Rheumatology/Kez532  0.356
2019 Kandane-Rathnayake R, Kent JR, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Golder V, Sockalingam S, Navarra SA, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, ... ... Nikpour M, et al. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. Lupus. 961203319887799. PMID 31718467 DOI: 10.1177/0961203319887799  0.424
2019 López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, Beretta L, Simeón CP, Carreira P, Ortego-Centeno N, Castellvi I, Bossini-Castillo L, Carmona FD, Orozco G, ... ... Nikpour M, et al. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications. 10: 4955. PMID 31672989 DOI: 10.1038/S41467-019-12760-Y  0.357
2019 Metwally M, Thabet K, Bayoumi A, Nikpour M, Stevens W, Sahhar J, Zochling J, Roddy J, Tymms K, Strickland G, Lester S, Rischmueller M, Ngian GS, Walker J, Hissaria P, et al. IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosis. Scientific Reports. 9: 14834. PMID 31619697 DOI: 10.1038/S41598-019-50709-9  0.367
2019 Morrisroe K, Hansen D, Huq M, Stevens W, Sahhar J, Ngian GS, Ferdowsi N, Hill C, Roddy J, Walker J, Proudman S, Nikpour M. Incidence, risk factors and outcomes of cancer in systemic sclerosis. Arthritis Care & Research. PMID 31539207 DOI: 10.1002/Acr.24076  0.35
2019 Fairley JL, Oon S, Saracino AM, Nikpour M. Management of cutaneous manifestations of lupus erythematosus: A systematic review. Seminars in Arthritis and Rheumatism. PMID 31526594 DOI: 10.1016/J.Semarthrit.2019.07.010  0.398
2019 Ross L, Stevens W, Wilson M, Strickland G, Walker J, Sahhar J, Ngian GS, Roddy J, Major G, Proudman S, Baron M, Nikpour M. Can patient-reported symptoms be used to measure disease activity in systemic sclerosis? Arthritis Care & Research. PMID 31421031 DOI: 10.1002/Acr.24053  0.428
2019 Oon S, Huq M, Nikpour M. Steroid sparing effect: an essential element in assessing therapeutic efficacy in SLE: response to 'Time to change the primary outcome of lupus trials' by Houssiau. Annals of the Rheumatic Diseases. PMID 31420326 DOI: 10.1136/Annrheumdis-2019-216113  0.357
2019 Nikpour M, Huq M, Oon S. Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter' by Sbeih . Annals of the Rheumatic Diseases. PMID 31285258 DOI: 10.1136/Annrheumdis-2019-215922  0.339
2019 Yeo AL, Koelmeyer R, Kandane-Rathnayake R, Golder V, Hoi A, Huq M, Hammond E, Nab H, Nikpour M, Morand EF. Lupus Low Disease Activity State is Associated with Reduced Direct Healthcare Costs in Patients with Systemic Lupus Erythematosus. Arthritis Care & Research. PMID 31282076 DOI: 10.1002/Acr.24023  0.413
2019 Nikpour M. Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to 'Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?' by Coudrec . Annals of the Rheumatic Diseases. PMID 31189552 DOI: 10.1136/Annrheumdis-2019-215797  0.384
2019 Quinlivan A, Proudman S, Sahhar J, Stevens W, Nikpour M. Cost savings with a novel algorithm for early detection of systemic sclerosis-related pulmonary arterial hypertension: alternative scenario analyses. Internal Medicine Journal. 49: 781-785. PMID 31185523 DOI: 10.1111/Imj.14316  0.305
2019 Ross L, Nikpour M. Gaining the Upper Hand on Systemic Sclerosis Digital Ulcers. The Journal of Rheumatology. 46: 548-549. PMID 31154442 DOI: 10.3899/Jrheum.180975  0.368
2019 Nikpour M. Disease activity and organ damage: different sides of the same coin in systemic sclerosis. Annals of the Rheumatic Diseases. PMID 31118191 DOI: 10.1136/Annrheumdis-2019-215639  0.373
2019 Parodis I, Nikpour M. How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials. Annals of the Rheumatic Diseases. PMID 31076392 DOI: 10.1136/Annrheumdis-2019-215650  0.335
2019 Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M, et al. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Annals of the Rheumatic Diseases. PMID 30928903 DOI: 10.1136/Annrheumdis-2018-214764  0.364
2019 Moxey J, Huq M, Proudman S, Sahhar J, Ngian GS, Walker J, Strickland G, Wilson M, Ross L, Major G, Roddy J, Stevens W, Nikpour M. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Research & Therapy. 21: 57. PMID 30764870 DOI: 10.1186/S13075-019-1839-5  0.4
2019 Ferdowsi N, Stevens W, Baron M, Nikpour M. Damage indices in rheumatic diseases: A systematic review of the literature. Seminars in Arthritis and Rheumatism. PMID 30745021 DOI: 10.1016/J.Semarthrit.2019.01.007  0.324
2019 Oon S, Huq M, Golder V, Ong PX, Morand EF, Nikpour M. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Annals of the Rheumatic Diseases. PMID 30679152 DOI: 10.1136/Annrheumdis-2018-214427  0.42
2019 Morand E, Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo SF, Lateef A, Sockalingam S, Navarra S, Hamijoyo L, Katsumata Y, Chan M, Hoi AY, Nikpour M. 26 Comparison of effects of DORIS remission and lupus low disease activity state (LLDAS) on disease outcomes in a multinational prospective study Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.26  0.428
2019 Choi C, Oon S, Nikpour M, Bae S. 259 Healthcare system affecting systemic lupus erythematosus in asia-pacific countries Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.259  0.387
2019 Morand E, Golder V, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo SF, Lateef A, Sockalingam S, Navarra S, Hamijoyo L, Katsumata Y, Chan M, Hoi AY, Nikpour M. 25 Prospective multicenter validation of the lupus low disease activity state (LLDAS) treatment target Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.25  0.43
2019 Apostolopoulos D, Kandane-Rathnayake R, Louthrenoo W, Luo SF, Wu Y, Lateef A, Golder V, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O’neill S, ... ... Nikpour M, et al. Thu0253 Effect Of Glucocorticoids On Damage Accrual In Sle Patients With No Clinical Or Serological Disease Activity Annals of the Rheumatic Diseases. DOI: 10.1136/Annrheumdis-2019-Eular.6449  0.413
2019 Golder V, Morand EF, Kandane-Rathnayake R, Huq M, Louthrenoo W, Luo SF, Wu Y, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, ... ... Nikpour M, et al. Op0330 #X00A0; Comparison Of The Effects Of Doris Remission And Lupus Low Disease Activity State (Lldas) On Disease Outcomes In A Multinational Prospective Study Annals of the Rheumatic Diseases. 78: 248-248. DOI: 10.1136/Annrheumdis-2019-Eular.5136  0.413
2019 Golder V, Morand EF, Kandane-Rathnayake R, Huq M, Nim H, Louthrenoo W, Luo SF, Wu Y, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, ... ... Nikpour M, et al. Op0246 Attainment Of The Lupus Low Disease Activity State Is Associated With Protection From Damage Accrual In Patients With Active Disease At Baseline Annals of the Rheumatic Diseases. 78: 203-203. DOI: 10.1136/Annrheumdis-2019-Eular.4457  0.445
2019 Golder V, Kandane-Rathnayake R, Huq M, Nim HT, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, ... ... Nikpour M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study The Lancet Rheumatology. 1: e95-e102. DOI: 10.1016/s2665-9913(19)30037-2  0.332
2018 Ross L, Baron M, Nikpour M. The challenges and controversies of measuring disease activity in systemic sclerosis. Journal of Scleroderma and Related Disorders. 3: 115-121. PMID 35382236 DOI: 10.1177/2397198318765061  0.326
2018 Patel S, Ross L, McKelvie P, Nikpour M. Constrictive pericarditis as the presenting manifestation of systemic sclerosis. Rheumatology (Oxford, England). PMID 30590804 DOI: 10.1093/Rheumatology/Key404  0.384
2018 Richard N, Hudson M, Wang M, Gyger G, Proudman S, Stevens W, Nikpour M, Baron M. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford, England). PMID 30517716 DOI: 10.1093/Rheumatology/Key350  0.409
2018 Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo SF, Jan Wu YJ, Li Z, An Y, Lateef A, Sockalingam S, Navarra SV, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, ... ... Nikpour M, et al. Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases. PMID 30398013 DOI: 10.1111/1756-185X.13431  0.307
2018 Ross L, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, Sahhar J, Ngian GS, Zochling J, Roddy J, Tymms K, Major G, Strickland G, Proudman SM, Nikpour M. The role of inflammatory markers in assessment of disease activity in systemic sclerosis. Clinical and Experimental Rheumatology. 36: 126-134. PMID 30277869 DOI: 10.1111/Imj.13772  0.407
2018 Ross L, Prior D, Proudman S, Vacca A, Baron M, Nikpour M. Defining primary systemic sclerosis heart involvement: A scoping literature review. Seminars in Arthritis and Rheumatism. PMID 30170705 DOI: 10.1016/J.Semarthrit.2018.07.008  0.396
2018 Wee E, Nikpour M, Balta S, Williams RA, Kelly RI. Lymphocytic thrombophilic arteritis complicated by systemic involvement. The Australasian Journal of Dermatology. PMID 29624649 DOI: 10.1111/Ajd.12798  0.324
2018 Connelly KL, Kandane-Rathnayake R, Huq M, Hoi A, Nikpour M, Morand EF. Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Scientific Reports. 8: 3268. PMID 29459655 DOI: 10.1038/S41598-018-20203-9  0.392
2018 Oon S, Huq M, Godfrey T, Nikpour M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. PMID 29426575 DOI: 10.1016/J.Semarthrit.2018.01.001  0.319
2018 Ross L, Baron M, Nikpour M. The challenges and controversies of measuring disease activity in systemic sclerosis Journal of Scleroderma and Related Disorders. 3: 115-121. DOI: 10.1177/2397198318765061  0.321
2018 Morand E, Kandane-Rathnayake R, Louthrenoo W, Luo S-, Wu Y-, Lateef A, Golder V, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O’Neill S, ... ... Nikpour M, et al. THU0350 Time dependent association of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus Annals of the Rheumatic Diseases. 77: 392-393. DOI: 10.1136/Annrheumdis-2018-Eular.4328  0.414
2018 Kandane-Rathnayake R, Golder V, Louthrenoo W, Luo S-, Wu Y-, Lateef A, Sockalingam S, Navarra S, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O’Neill S, Goldblatt F, ... ... Nikpour M, et al. SAT0430 Assessment of acr and slicc classification criteria in the asia pacific lupus collaboration cohort Annals of the Rheumatic Diseases. 77: 1074-1074. DOI: 10.1136/Annrheumdis-2018-Eular.4308  0.41
2017 Morrisroe K, Sudararajan V, Stevens W, Sahhar J, Zochling J, Roddy J, Proudman S, Nikpour M. Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. Rheumatology (Oxford, England). PMID 29155994 DOI: 10.1093/Rheumatology/Kex362  0.302
2017 Morrisroe K, Stevens W, Proudman S, Nikpour M. A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults. International Journal of Rheumatic Diseases. PMID 29076640 DOI: 10.1111/1756-185X.13203  0.364
2017 Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS, Celermajer D, Zochling J, Proudman S, Nikpour M. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Research & Therapy. 19: 122. PMID 28576149 DOI: 10.1186/S13075-017-1341-X  0.325
2017 Mejia Otero C, Assassi S, Hudson M, Mayes MD, Estrada-Y-Martin R, Pedroza C, Mills TW, Walker J, Baron M, Stevens W, Proudman SM, Nikpour M, Mehra S, Wang M, Fritzler MJ, et al. Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. The Journal of Rheumatology. PMID 28365584 DOI: 10.3899/Jrheum.160574  0.368
2017 Boulos D, Ngian GS, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease. International Journal of Rheumatic Diseases. PMID 28337853 DOI: 10.1111/1756-185X.13035  0.305
2017 Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, ... ... Nikpour M, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Research & Therapy. 19: 62. PMID 28320433 DOI: 10.1186/S13075-017-1256-6  0.411
2017 Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Arthritis Research & Therapy. 19: 42. PMID 28270192 DOI: 10.1186/S13075-017-1250-Z  0.346
2017 Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau CS, Lee AL, Navarra ST, Godfrey T, Oon S, Hoi AY, Morand EF, Nikpour M. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study. Seminars in Arthritis and Rheumatism. PMID 28216192 DOI: 10.1016/J.Semarthrit.2017.01.007  0.402
2017 Golder V, Huq M, Franklyn K, Calderone A, Lateef A, Lau C, Lee A, Navarra S, Godfrey T, Oon S, Hoi A, Morand E, Nikpour M. 437 Construct validity assessment of the lupus low disease activity state (lldas) – a case based validity study Lupus Science & Medicine. 4. DOI: 10.1136/Lupus-2017-000215.437  0.352
2017 Golder V, Kandane-rathnayake R, Hoi A, Huq M, Louthrenoo W, An Y, Li Z, Luo S, Sockalingam S, Lau C, Mok M, Lateef A, Navarra S, Wu Y, Hamijoyo L, ... ... Nikpour M, et al. 33 Association of the lupus low disease activity state (lldas) with health related quality of life Lupus Science & Medicine. 4. DOI: 10.1136/Lupus-2017-000215.33  0.425
2016 Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, Tatibouet S, Carmona L, Joven BE, Huq M, Proudman S, Nikpour M. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis & Rheumatology (Hoboken, N.J.). PMID 28029745 DOI: 10.1002/Art.40027  0.348
2016 Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, Hoi A, Nikpour M, Morand EF. Independent association of glucocorticoids with damage accrual in SLE. Lupus Science & Medicine. 3: e000157. PMID 27933196 DOI: 10.1136/Lupus-2016-000157  0.35
2016 Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong PK, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, ... ... Nikpour M, et al. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. Bmj Open. 6: e011028. PMID 27932335 DOI: 10.1136/Bmjopen-2016-011028  0.374
2016 Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, ... ... Nikpour M, et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Research & Therapy. 18: 260. PMID 27829463 DOI: 10.1186/S13075-016-1163-2  0.451
2016 Nikpour M. Response to: 'Remission in systemic lupus erythematosus: durable remission is rare' by Wilhelm et al. Annals of the Rheumatic Diseases. PMID 27797751 DOI: 10.1136/Annrheumdis-2016-210560  0.414
2016 Esposito J, Brown Z, Stevens W, Sahhar J, Rabusa C, Zochling J, Roddy J, Walker J, Proudman SM, Nikpour M. The association of low complement with disease activity in systemic sclerosis: a prospective cohort study. Arthritis Research & Therapy. 18: 246. PMID 27770830 DOI: 10.1186/S13075-016-1147-2  0.474
2016 Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Nikpour M. Measures of disease status in systemic sclerosis: A systematic review. Seminars in Arthritis and Rheumatism. PMID 27765344 DOI: 10.1016/J.Semarthrit.2016.07.010  0.433
2016 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study. Bmc Pulmonary Medicine. 16: 134. PMID 27677579 DOI: 10.1186/S12890-016-0296-Z  0.396
2016 Connelly KL, Kandane-Rathnayake R, Hoi A, Nikpour M, Morand EF. Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus. Scientific Reports. 6: 29909. PMID 27453287 DOI: 10.1038/Srep29909  0.427
2016 Morrisroe K, Frech T, Schniering J, Maurer B, Nikpour M. Systemic sclerosis: The need for structured care. Best Practice & Research. Clinical Rheumatology. 30: 3-21. PMID 27421213 DOI: 10.1016/J.Berh.2016.04.004  0.395
2016 Nikpour M, Prior D, Celermajer D. Letter by Nikpour et al Regarding Article, "Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)". Circulation. 133: e661. PMID 27185030 DOI: 10.1161/Circulationaha.116.021847  0.329
2016 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. SAT0235 Survival in Systemic Sclerosis Related Pulmonary Arterial Hypertension in The Modern Treatment Era: Results from A Multicentre Australian Cohort Study Annals of the Rheumatic Diseases. 75: 753-754. DOI: 10.1136/Annrheumdis-2016-Eular.5368  0.35
2016 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. AB0607 Determinants of Unemployment amongst Australian Systemic Sclerosis Patients: Table 1. Annals of the Rheumatic Diseases. 75: 1112-1112. DOI: 10.1136/Annrheumdis-2016-Eular.5354  0.403
2016 Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman S, Nikpour M. FRI0249 Risk Factors for Development of Pulmonary Arterial Hypertension in Australian Scleroderma Patients Annals of the Rheumatic Diseases. 75: 524-524. DOI: 10.1136/Annrheumdis-2016-Eular.5005  0.395
2016 Khanna D, Produman S, Frech T, Nihtyanova S, Domsic R, Berrocal V, Stevens W, Nikpour M, Denton C. FRI0271 Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma–Analysis from 4 Cohorts: Table 1 Annals of the Rheumatic Diseases. 75: 533-533. DOI: 10.1136/Annrheumdis-2016-Eular.3781  0.431
2016 Boulos D, Rajadurai A, Ngian GS, Elford K, Stevens W, Proudman S, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J. FRI0266 Long-Term Efficacy and Tolerability of Mycophenolate Mofetil Therapy in Diffuse Scleroderma Skin Disease Annals of the Rheumatic Diseases. 75: 531-531. DOI: 10.1136/Annrheumdis-2016-Eular.3372  0.382
2016 Golder V, Kandane-Rathnayake R, Hoi A, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MYT, Lateef A, Franklyn K, Navarra SV, Zamora L, ... ... Nikpour M, et al. SAT0282 Frequency and Predictors of Attainment of The Lupus Low Disease Activity State (LLDAS) in A Cross Sectional Study of Sle Patients in The Asia Pacific Annals of the Rheumatic Diseases. 75: 770-770. DOI: 10.1136/Annrheumdis-2016-Eular.1752  0.466
2015 Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Annals of the Rheumatic Diseases. PMID 26458737 DOI: 10.1136/Annrheumdis-2015-207726  0.485
2015 Papachristos DA, Nikpour M, Hair C, Stevens WM. Intravenous cyclophosphamide as a therapeutic option for severe refractory gastric antral vascular ectasia in systemic sclerosis. Internal Medicine Journal. 45: 1077-81. PMID 26429218 DOI: 10.1111/Imj.12883  0.331
2015 Quinlivan A, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, ... ... Nikpour M, et al. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Internal Medicine Journal. PMID 26337683 DOI: 10.1111/Imj.12890  0.327
2015 Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, Assassi S, Mayes MD, Tatibouet S, Wang M, Baron M, Fritzler MJ. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity. 1-10. PMID 26334795 DOI: 10.3109/08916934.2015.1077231  0.308
2015 Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG. Interpretation of an extended auto-antibody profile in a well characterised Australian systemic sclerosis (scleroderma) cohort utilising Principle Components Analysis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 26246178 DOI: 10.1002/Art.39316  0.421
2015 Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal Manifestations of Systemic Sclerosis. Rheumatic Diseases Clinics of North America. 41: 507-18. PMID 26210132 DOI: 10.1016/J.Rdc.2015.04.011  0.419
2015 Yap KS, Northcott M, Hoi AB, Morand EF, Nikpour M. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Science & Medicine. 2: e000064. PMID 25893106 DOI: 10.1136/Lupus-2014-000064  0.327
2015 Thakkar V, Nikpour M, Stevens WM, Proudman SM. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension. Internal Medicine Journal. 45: 248-54. PMID 25735576 DOI: 10.1111/Imj.12691  0.368
2015 Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, ... ... Nikpour M, et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Research & Therapy. 17: 7. PMID 25596924 DOI: 10.1186/S13075-015-0517-5  0.329
2014 Osthoff M, Ngian GS, Dean MM, Nikpour M, Stevens W, Proudman S, Eisen DP, Sahhar J. Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study. Arthritis Research & Therapy. 16: 480. PMID 25403109 DOI: 10.1186/S13075-014-0480-6  0.339
2014 Nikpour M, Bridge JA, Richter S. A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: Identifying areas of unmet need Internal Medicine Journal. 44: 1170-1179. PMID 25169712 DOI: 10.1111/Imj.12568  0.379
2014 Franklyn K, Hoi A, Nikpour M, Morand EF. The need to define treatment goals for systemic lupus erythematosus. Nature Reviews. Rheumatology. 10: 567-71. PMID 25048762 DOI: 10.1038/Nrrheum.2014.118  0.4
2014 Quinlivan A, Thakkar V, Stevens W, Prior D, Rabusa C, Youssef P, Gabbay E, Roddy J, Walker J, Zochling J, Sahhar J, Nash P, Lester S, Hill C, Rischmueller M, ... ... Nikpour M, et al. Cost savings with a biomarker-based screening algorithm for pulmonary arterial hypertension in systemic sclerosis Internal Medicine Journal. 44: 5-5. PMID 24735068 DOI: 10.1111/Imj.12424  0.308
2014 Quinlivan A, Moore OA, Romas E, Nikpour M. Whose responsibility is it to assess cardiovascular risk in patients with rheumatoid arthritis? Internal Medicine Journal. 44: 108-109. PMID 24450531 DOI: 10.1111/Imj.12322  0.329
2014 Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Current Opinion in Rheumatology. 26: 131-7. PMID 24441644 DOI: 10.1097/Bor.0000000000000027  0.39
2014 Vacca A, Meune C, Gordon J, Chung L, Proudman S, Assassi S, Nikpour M, Rodriguez-Reyna TS, Khanna D, Lafyatis R, Matucci-Cerinic M, Distler O, Allanore Y. Cardiac arrhythmias and conduction defects in systemic sclerosis. Rheumatology (Oxford, England). 53: 1172-7. PMID 24241036 DOI: 10.1093/Rheumatology/Ket377  0.384
2014 Lester S, Patterson K, Walker J, Charlesworth J, Stankovich J, Stevens W, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Rischmueller M, Proudman S, Brown M, Zochling J. Associations Between Hla Drb1 Alleles and Autoantibodies in Systemic Sclerosis Internal Medicine Journal. 44: 2-2. DOI: 10.1111/Imj.12428  0.319
2013 Arayssi T, Touma Z, Nikpour M, Ghandour L. The assessment of disease activity in rheumatic diseases. International Journal of Rheumatology. 2013: 275691. PMID 24307902 DOI: 10.1155/2013/275691  0.632
2013 Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, Roddy J, Walker JG, Zochling J, Sahhar J, Nash P, Lester S, Rischmueller M, Proudman SM, Nikpour M. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Research & Therapy. 15: R193. PMID 24246100 DOI: 10.1186/Ar4383  0.316
2013 Nikpour M, Gladman DD, Ibanez D, Harvey PJ, Urowitz MB. Assessment of coronary risk based on cumulative exposure to lipids in systemic lupus erythematosus. The Journal of Rheumatology. 40: 2006-14. PMID 24128779 DOI: 10.3899/Jrheum.121273  0.499
2013 Nikpour M, Gladman DD, Urowitz MB. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? Lupus. 22: 1243-50. PMID 24097996 DOI: 10.1177/0961203313493031  0.545
2013 Nikpour M, Stevens W, Proudman SM, Buchbinder R, Prior D, Zochling J, Williams T, Gabbay E, Nandurkar H. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated? Internal Medicine Journal. 43: 599-603. PMID 23668273 DOI: 10.1111/Imj.12111  0.393
2013 Thakkar V, Stevens WM, Moore OA, Nikpour M. Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review. Internal Medicine Journal. 43: 751-60. PMID 23611651 DOI: 10.1111/Imj.12167  0.337
2013 Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, Nived O, Hanly JG, Landolt-Marticorena C, Tam LS, Toloza S, Nikpour M, Riddell C, Steiman A, Eder L, et al. Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. The Journal of Rheumatology. 40: 34-9. PMID 23118108 DOI: 10.3899/Jrheum.120754  0.623
2013 Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Gabbay E, Youssef P, Nash P, Zochling J, Proudman SM, Stevens W, ... Nikpour M, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford, England). 52: 155-60. PMID 23065360 DOI: 10.1093/Rheumatology/Kes289  0.335
2013 Lau CS, Nikpour M, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Hoi A, Morand EF. THU0298 Consensus Definition of a Low Disease Activity State in Systemic Lupus Erythematosus Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.826  0.449
2013 Nikpour M, Baron M, Hudson M, Carreira P, Hunzelmann N, Frech T, Sahhar J, Nash P, Roddy J, Schrieber L, Stevens W, Proudman S. SAT0202 Early Accrual of Organ Damage in Systemic Sclerosis: Rationale for Forming a Multinational Inception Cohort of Patients with Scleroderma (The Insync Study) Annals of the Rheumatic Diseases. 72: A649.1-A649. DOI: 10.1136/Annrheumdis-2013-Eular.1928  0.389
2013 Nikpour M, Baron M, Hudson M, Carreira P, Hunzelmann N, Frech T, Sahhar J, Nash P, Major G, Youssef P, Roddy J, Zochling J, Proudman S, Stevens W. FRI0372 Early mortality in systemic sclerosis: rationale for forming a multinational inception cohort of patients with scleroderma (the insync study) Annals of the Rheumatic Diseases. 72: A499.1-A499. DOI: 10.1136/Annrheumdis-2013-Eular.1499  0.389
2013 Morrisroe K, Stevens W, Byron J, Thakkar V, Moore O, Proudman S, Nikpour M. FRI0261 Anti-phospholipid antibodies in systemic sclerosis: Prevalence and clinical correlations Annals of the Rheumatic Diseases. 71: 402.2-402. DOI: 10.1136/Annrheumdis-2012-Eular.2718  0.369
2013 Moore O, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M. FRI0243 Extent of disease on high-resolution CT lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease Annals of the Rheumatic Diseases. 71: 396.2-396. DOI: 10.1136/Annrheumdis-2012-Eular.2700  0.406
2013 Thakkar V, Stevens W, Prior D, Moore O, Byron J, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Celermajer D, Gabbay E, Youssef P, ... ... Nikpour M, et al. THU0258 N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis Annals of the Rheumatic Diseases. 71: 242.1-242. DOI: 10.1136/Annrheumdis-2012-Eular.2223  0.356
2013 Moore O, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, Byron J, Sahhar J, Roddy J, Youssef P, Nash P, Zochling J, Proudman S, Stevens W, Nikpour M. THU0235 Identifying and quantifying prognostic factors in systemic sclerosis-related interstitial lung disease using a time-varying covariate survival model Annals of the Rheumatic Diseases. 71: 234.3-235. DOI: 10.1136/Annrheumdis-2012-Eular.2200  0.425
2012 Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, Minson R, Hill C, Chow K, Sahhar J, Proudman S, Nikpour M. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Research & Therapy. 14: R213. PMID 23039366 DOI: 10.1186/Ar4051  0.332
2012 Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects Internal Medicine Journal. 42: 968-978. PMID 22827853 DOI: 10.1111/J.1445-5994.2012.02886.X  0.438
2012 Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, Patterson K, Hissaria P, Roddy J, Zochling J, Sahhar J, Nash P, Tymms K, Celermajer D, Gabbay E, ... ... Nikpour M, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: A case-control study Arthritis Research and Therapy. 14. PMID 22691291 DOI: 10.1186/Ar3876  0.323
2012 Nikpour M, Harvey PJ, Ibanez D, Gladman DD, Urowitz MB. High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. Arthritis and Rheumatism. 64: 3052-3. PMID 22614710 DOI: 10.1002/Art.34541  0.519
2011 Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort Arthritis Research and Therapy. 13. PMID 22189167 DOI: 10.1186/Ar3544  0.372
2011 Nikpour M, Urowitz MB, Ibanez D, Harvey PJ, Gladman DD. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. Arthritis Research & Therapy. 13: R156. PMID 21955652 DOI: 10.1186/Ar3473  0.58
2011 Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. Lupus. 20: 299-304. PMID 21078763 DOI: 10.1177/0961203310381512  0.516
2011 Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. The Journal of Rheumatology. 38: 60-3. PMID 21078718 DOI: 10.3899/Jrheum.100575  0.675
2010 Nikpour M, Stevens WM, Herrick AL, Proudman SM. Epidemiology of systemic sclerosis. Best Practice & Research. Clinical Rheumatology. 24: 857-69. PMID 21665131 DOI: 10.1016/J.Berh.2010.10.007  0.423
2010 Nikpour M, Gladman DD, Ibanez D, Harvey PJ, Urowitz MB. Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. Arthritis Research & Therapy. 12: R125. PMID 20591138 DOI: 10.1186/Ar3063  0.563
2010 Nikpour M. Guilt by association: the challenge of teasing apart the effect of various risk factors for coronary heart disease in systemic lupus erythematosus. The Journal of Rheumatology. 37: 217-9. PMID 20147475 DOI: 10.3899/Jrheum.091287  0.425
2010 Nikpour M, Proudman SM, Goh NS, Moutsopoulos HM. Interstitial lung disease in Sjogren's syndrome Current Rheumatology Reviews. 6: 127-137. DOI: 10.2174/157339710791330687  0.341
2009 Goldberg RJ, Urowitz MB, Ibañez D, Nikpour M, Gladman DD. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. The Journal of Rheumatology. 36: 2454-61. PMID 19833754 DOI: 10.3899/Jrheum.090011  0.565
2009 Nikpour M, Gladman DD, Ibañez D, Urowitz MB. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus. 18: 966-73. PMID 19762397 DOI: 10.1177/0961203309105130  0.587
2009 Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis and Rheumatism. 61: 1152-8. PMID 19714602 DOI: 10.1002/Art.24741  0.586
2009 Nikpour M, Urowitz MB, Gladman DD. Epidemiology of atherosclerosis in systemic lupus erythematosus. Current Rheumatology Reports. 11: 248-54. PMID 19691927 DOI: 10.1007/S11926-009-0035-Z  0.537
2009 Nikpour M, Gladman DD, Ibañez D, Bruce IN, Burns RJ, Urowitz MB. Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. The Journal of Rheumatology. 36: 288-94. PMID 19208561 DOI: 10.3899/Jrheum.080776  0.534
2008 Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Annals of the Rheumatic Diseases. 67: 1069-75. PMID 18063674 DOI: 10.1136/Ard.2007.074765  0.504
2006 Lee AB, Godfrey T, Rowley KG, Karschimkus CS, Dragicevic G, Romas E, Clemens L, Wilson AM, Nikpour M, Prior DL, Best JD, Jenkins AJ. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Internal Medicine Journal. 36: 237-43. PMID 16640741 DOI: 10.1111/J.1445-5994.2006.01044.X  0.393
2005 Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheumatic Diseases Clinics of North America. 31: 329-54, vii-viii. PMID 15922149 DOI: 10.1016/j.rdc.2005.01.001  0.541
2004 NIKPOUR M. Relationship between myocardial perfusion scinti-graphy and brachial artery endothelial function in systemic lupus erythematosus Journal of Nuclear Cardiology. 11: S31-S32. DOI: 10.1016/J.Nuclcard.2004.06.101  0.379
Show low-probability matches.